NTRK1 and malaria: While neither of these strategies is entirely specific to inhibiting or blocking EphA2 as Nilotinib can act on other receptor tyrosine kinases and recombinant EphA2-Fc treatment will also prevent ephrin ligands from binding to other EphA receptors, these data demonstrate that blocking EphA2 signaling or interaction with its cognate ephrin ligands is a feasible strategy for preventing BBB breakdown during malaria.